{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,5]],"date-time":"2026-01-05T17:27:21Z","timestamp":1767634041064,"version":"3.48.0"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2025,10,14]],"date-time":"2025-10-14T00:00:00Z","timestamp":1760400000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,10,14]],"date-time":"2025-10-14T00:00:00Z","timestamp":1760400000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Surg Oncol"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1245\/s10434-025-18556-3","type":"journal-article","created":{"date-parts":[[2025,10,14]],"date-time":"2025-10-14T13:26:07Z","timestamp":1760448367000},"page":"1748-1759","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Comparison of Familial and Sporadic Pancreatic Cancer: Clinicopathological and Genomic Features"],"prefix":"10.1245","volume":"33","author":[{"given":"Yuya","family":"Miura","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sumiko","family":"Ohnami","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keiichi","family":"Ohshima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takeshi","family":"Nagashima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yukiyasu","family":"Okamura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keiichi","family":"Hatakeyama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenichi","family":"Urakami","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasuto","family":"Akiyama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryo","family":"Ashida","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katsuhisa","family":"Ohgi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshiyasu","family":"Kato","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shimpei","family":"Otsuka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hideyuki","family":"Dei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katsuhiko","family":"Uesaka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ken","family":"Yamaguchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Teiichi","family":"Sugiura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,10,14]]},"reference":[{"issue":"23","key":"18556_CR1","doi-asserted-by":"publisher","first-page":"3669","DOI":"10.1002\/cncr.28863","volume":"120","author":"JL Humphris","year":"2014","unstructured":"Humphris JL, Johns AL, Simpson SH, Cowley MJ, Pajic M, Chang DK, Nagrial AM, Chin VT, Chantrill LA, Pinese M, Mead RS, Gill AJ, Samra JS, Kench JG, Musgrove EA, Tucker KM, Spigelman AD, Waddell N, Grimmond SM, Biankin AV, Australian Pancreatic Cancer Genome Initiative. Clinical and pathologic features of familial pancreatic cancer. Cancer. 2014;120(23):3669\u201375. https:\/\/doi.org\/10.1002\/cncr.28863.","journal-title":"Cancer."},{"issue":"12","key":"18556_CR2","doi-asserted-by":"publisher","first-page":"2722","DOI":"10.1002\/cncr.20700","volume":"101","author":"TA James","year":"2004","unstructured":"James TA, Sheldon DG, Rajput A, Kuvshinoff BW, Javle MM, Nava HR, Smith JL, Gibbs JF. Risk factors associated with earlier age of onset in familial pancreatic carcinoma. Cancer. 2004;101(12):2722\u20136. https:\/\/doi.org\/10.1002\/cncr.20700.","journal-title":"Cancer."},{"issue":"6","key":"18556_CR3","doi-asserted-by":"publisher","first-page":"902","DOI":"10.1002\/ijc.20210","volume":"110","author":"DK Bartsch","year":"2004","unstructured":"Bartsch DK, Kress R, Sina-Frey M, Gr\u00fctzmann R, Gerdes B, Pilarsky C, Heise JW, Schulte KM, Colombo-Benkmann M, Schleicher C, Witzigmann H, Prid\u00f6hl O, Ghadimi MB, Horstmann O, von Bernstorff W, Jochimsen L, Schmidt J, Eisold S, Est\u00e9v\u00e9z-Schwarz L, Hahn SA, Schulmann K, B\u00f6ck W, Gress TM, Z\u00fcgel N, Breitschaft K, Prenzel K, Messmann H, Endlicher E, Schneider M, Ziegler A, Schmiegel W, Sch\u00e4fer H, Rothmund M, Rieder H. Prevalence of familial pancreatic cancer in Germany. Int J Cancer. 2004;110(6):902\u20136. https:\/\/doi.org\/10.1002\/ijc.20210.","journal-title":"Int J Cancer."},{"issue":"3","key":"18556_CR4","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1002\/jhbp.12112","volume":"32","author":"H Matsubayashi","year":"2025","unstructured":"Matsubayashi H, Kiyozumi Y, Ono H. Genetic medicine of familial and hereditary pancreatic cancer: recent update in the era of precision cancer medicine. J Hepatobiliary Pancreat Sci. 2025;32(3):212\u201327. https:\/\/doi.org\/10.1002\/jhbp.12112.","journal-title":"J Hepatobiliary Pancreat Sci."},{"issue":"8","key":"18556_CR5","doi-asserted-by":"publisher","first-page":"1503","DOI":"10.1007\/s00432-018-2666-9","volume":"144","author":"A Kowalewski","year":"2018","unstructured":"Kowalewski A, Szylberg \u0141, Saganek M, Napiontek W, Antosik P, Grzanka D. Emerging strategies in BRCA-positive pancreatic cancer. J Cancer Res Clin Oncol. 2018;144(8):1503\u20137. https:\/\/doi.org\/10.1007\/s00432-018-2666-9.","journal-title":"J Cancer Res Clin Oncol."},{"issue":"4","key":"18556_CR6","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1016\/j.jamcollsurg.2017.12.021","volume":"226","author":"AB Blair","year":"2018","unstructured":"Blair AB, Groot VP, Gemenetzis G, Wei J, Cameron JL, Weiss MJ, Goggins M, Wolfgang CL, Yu J, He J. BRCA1\/BRCA2 germline mutation carriers and sporadic pancreatic ductal adenocarcinoma. J Am Coll Surg. 2018;226(4):630-637.e1. https:\/\/doi.org\/10.1016\/j.jamcollsurg.2017.12.021.","journal-title":"J Am Coll Surg."},{"issue":"4","key":"18556_CR7","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1056\/NEJMoa1903387","volume":"381","author":"T Golan","year":"2019","unstructured":"Golan T, Hammel P, Reni M, Van Cutsem E, Macarulla T, Hall MJ, Park JO, Hochhauser D, Arnold D, Oh DY, Reinacher-Schick A, Tortora G, Alg\u00fcl H, O\u2019Reilly EM, McGuinness D, Cui KY, Schlienger K, Locker GY, Kindler HL. Maintenance olaparib for germline BRCA-mutated metastatic pancreatic cancer. N Engl J Med. 2019;381(4):317\u201327. https:\/\/doi.org\/10.1056\/NEJMoa1903387.","journal-title":"N Engl J Med."},{"issue":"30","key":"18556_CR8","doi-asserted-by":"publisher","first-page":"3382","DOI":"10.1200\/JCO.2017.72.3502","volume":"35","author":"K Shindo","year":"2017","unstructured":"Shindo K, Yu J, Suenaga M, Fesharakizadeh S, Cho C, Macgregor-Das A, Siddiqui A, Witmer PD, Tamura K, Song TJ, Navarro Almario JA, Brant A, Borges M, Ford M, Barkley T, He J, Weiss MJ, Wolfgang CL, Roberts NJ, Hruban RH, Klein AP, Goggins M. Deleterious germline mutations in patients with apparently sporadic pancreatic adenocarcinoma. J Clin Oncol. 2017;35(30):3382\u201390. https:\/\/doi.org\/10.1200\/JCO.2017.72.3502.","journal-title":"J Clin Oncol."},{"key":"18556_CR9","unstructured":"National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology. Pancreatic Adenocarcinoma. Version 2. 2025. https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/pancreatic.pdf. Accessed 10 June 2025."},{"issue":"8","key":"18556_CR10","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1093\/oncolo\/oyad178","volume":"28","author":"KT Chen","year":"2023","unstructured":"Chen KT, Madison R, Moore J, Jin D, Fleischmann Z, Newberg J, Schrock A, Bhardwaj N, Lofgren KT, He J, Frampton G, Hegde P, Fabrizio D, Pishvaian MJ, Ebot E, Singhi A, Sokol E. A novel HRD signature is predictive of FOLFIRINOX benefit in metastatic pancreatic cancer. Oncologist. 2023;28(8):691\u20138. https:\/\/doi.org\/10.1093\/oncolo\/oyad178.","journal-title":"Oncologist."},{"issue":"6","key":"18556_CR11","doi-asserted-by":"publisher","first-page":"oyaf141","DOI":"10.1093\/oncolo\/oyaf141","volume":"30","author":"B Jiang","year":"2025","unstructured":"Jiang B, Shang Y, Zhang X, He W, Hua H, Ye F, Zhou X, Li Y, Zhong W, Jiang W, Wu G. The prognostic and predictive value of homologous recombination deficiency in gastrointestinal cancer. Oncologist. 2025;30(6):oyaf141. https:\/\/doi.org\/10.1093\/oncolo\/oyaf141.","journal-title":"Oncologist."},{"issue":"6","key":"18556_CR12","doi-asserted-by":"publisher","first-page":"407","DOI":"10.2220\/biomedres.35.407","volume":"35","author":"K Yamaguchi","year":"2014","unstructured":"Yamaguchi K, Urakami K, Ohshima K, Mochizuki T, Akiyama Y, Uesaka K, et al. Implementation of individualized medicine for cancer patients by multiomics-based analyses-the project HOPE. Biomed Res. 2014;35(6):407\u201312. https:\/\/doi.org\/10.2220\/biomedres.35.407.","journal-title":"Biomed Res."},{"issue":"3","key":"18556_CR13","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1002\/ags3.12636","volume":"7","author":"T Imamura","year":"2022","unstructured":"Imamura T, Ashida R, Ohshima K, Uesaka K, Sugiura T, Okamura Y, Ohgi K, Ohnami S, Nagashima T, Yamaguchi K. Genomic landscape of pancreatic cancer in the Japanese version of the cancer genome atlas. Ann Gastroenterol Surg. 2022;7(3):491\u2013502. https:\/\/doi.org\/10.1002\/ags3.12636.","journal-title":"Ann Gastroenterol Surg."},{"issue":"5","key":"18556_CR14","doi-asserted-by":"publisher","first-page":"e510","DOI":"10.1097\/SLA.0000000000004535","volume":"276","author":"S Takahashi","year":"2020","unstructured":"Takahashi S, Ohno I, Ikeda M, et al. Neoadjuvant S-1 with concurrent radiotherapy followed by surgery for borderline resectable pancreatic cancer: a phase II open-label multicenter prospective trial (JASPAC05). Ann Surg. 2020;276(5):e510\u20137.","journal-title":"Ann Surg."},{"key":"18556_CR15","doi-asserted-by":"publisher","first-page":"1394","DOI":"10.1016\/j.ejso.2016.01.006","volume":"42","author":"B Ielpo","year":"2016","unstructured":"Ielpo B, Duran H, Diaz E, et al. Preoperative treatment with gemcitabine plus nab-paclitaxel is a safe and effective chemotherapy for pancreatic adenocarcinoma. Eur J Surg Oncol. 2016;42:1394\u2013400.","journal-title":"Eur J Surg Oncol."},{"key":"18556_CR16","doi-asserted-by":"publisher","first-page":"e161137","DOI":"10.1001\/jamasurg.2016.1137","volume":"151","author":"MH Katz","year":"2016","unstructured":"Katz MH, Shi Q, Ahmad SA, et al. Preoperative modified FOLFIRINOX treatment followed by capecitabine-based chemoradiation for borderline resectable pancreatic cancer: alliance for clinical trials in oncology trial A021101. JAMA Surg. 2016;151:e161137.","journal-title":"JAMA Surg."},{"key":"18556_CR17","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1093\/jjco\/hyy190","volume":"49","author":"F Motoi","year":"2019","unstructured":"Motoi F, Kosuge T, Ueno H, et al. Randomized phase II\/III trial of neoadjuvant chemotherapy with gemcitabine and S-1 versus upfront surgery for resectable pancreatic cancer (Prep-02\/JSAP05). Jpn J Clin Oncol. 2019;49:190\u20134.","journal-title":"Jpn J Clin Oncol."},{"key":"18556_CR18","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1016\/S0140-6736(16)30583-9","volume":"388","author":"K Uesaka","year":"2016","unstructured":"Uesaka K, Boku N, Fukutomi A, et al. Adjuvant chemotherapy of S-1 versus gemcitabine for resected pancreatic cancer: a phase 3, open-label, randomised, non-inferiority trial (JASPAC 01). Lancet. 2016;388:248\u201357.","journal-title":"Lancet."},{"issue":"2","key":"18556_CR19","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1111\/cas.14290","volume":"111","author":"T Nagashima","year":"2020","unstructured":"Nagashima T, Yamaguchi K, Urakami K, Shimoda Y, Ohnami S, Ohshima K, et al. Japanese version of the cancer genome atlas, JCGA, established using fresh frozen tumors obtained from 5143 cancer patients. Cancer Sci. 2020;111(2):687\u201399. https:\/\/doi.org\/10.1111\/cas.14290.","journal-title":"Cancer Sci."},{"key":"18556_CR20","doi-asserted-by":"publisher","first-page":"1776","DOI":"10.1038\/bjc.2012.451","volume":"107","author":"V Abkevich","year":"2012","unstructured":"Abkevich V, Timms KM, Hennessy BT, Potter J, Carey MS, Meyer LA, et al. Patterns of genomic loss of heterozygosity predict homologous recombination repair defects in epithelial ovarian cancer. Br J Cancer. 2012;107:1776\u201382.","journal-title":"Br J Cancer."},{"key":"18556_CR21","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1158\/2159-8290.CD-11-0206","volume":"2","author":"NJ Birkbak","year":"2012","unstructured":"Birkbak NJ, Wang ZC, Kim J-Y, Eklund AC, Li Q, Tian R, et al. Telomeric allelic imbalance indicates defective DNA repair and sensitivity to DNA-damaging agents. Cancer Discov. 2012;2:366\u201375.","journal-title":"Cancer Discov."},{"key":"18556_CR22","doi-asserted-by":"publisher","first-page":"5454","DOI":"10.1158\/0008-5472.CAN-12-1470","volume":"72","author":"T Popova","year":"2012","unstructured":"Popova T, Manie E, Rieunier G, Caux-Moncoutier V, Tirapo C, Dubois T, et al. Ploidy and large-scale genomic instability consistently identify basal-like breast carcinomas with BRCA1\/2 inactivation. Cancer Res. 2012;72:5454\u201362.","journal-title":"Cancer Res."},{"issue":"15","key":"18556_CR23","doi-asserted-by":"publisher","first-page":"3764","DOI":"10.1158\/1078-0432.CCR-15-2477","volume":"22","author":"ML Telli","year":"2016","unstructured":"Telli ML, Timms KM, Reid J, Hennessy B, Mills GB, Jensen KC, Szallasi Z, Barry WT, Winer EP, Tung NM, Isakoff SJ, Ryan PD, Greene-Colozzi A, Gutin A, Sangale Z, Iliev D, Neff C, Abkevich V, Jones JT, Lanchbury JS, Hartman AR, Garber JE, Ford JM, Silver DP, Richardson AL. Homologous recombination deficiency (HRD) score predicts response to platinum-containing neoadjuvant chemotherapy in patients with triple-negative breast cancer. Clin Cancer Res. 2016;22(15):3764\u201373. https:\/\/doi.org\/10.1158\/1078-0432.CCR-15-2477.","journal-title":"Clin Cancer Res."},{"issue":"1","key":"18556_CR24","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1038\/s41598-017-00219-3","volume":"7","author":"K Ohshima","year":"2017","unstructured":"Ohshima K, Hatakeyama K, Nagashima T, Watanabe Y, Kanto K, Doi Y, Ide T, Shimoda Y, Tanabe T, Ohnami S, et al. Integrated analysis of gene expression and copy number identified potential cancer driver genes with amplification-dependent overexpression in 1454 solid tumors. Sci Rep. 2017;7(1):641. https:\/\/doi.org\/10.1038\/s41598-017-00219-3.","journal-title":"Sci Rep."},{"issue":"7","key":"18556_CR25","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1038\/s41587-019-0114-2","volume":"37","author":"AM Newman","year":"2019","unstructured":"Newman AM, Steen CB, Liu CL, Gentles AJ, Chaudhuri AA, Scherer F, Khodadoust MS, Esfahani MS, Luca BA, Steiner D, Diehn M, Alizadeh AA. Determining cell type abundance and expression from bulk tissues with digital cytometry. Nat Biotechnol. 2019;37(7):773\u201382. https:\/\/doi.org\/10.1038\/s41587-019-0114-2.","journal-title":"Nat Biotechnol."},{"issue":"D1","key":"18556_CR26","doi-asserted-by":"publisher","first-page":"D587","DOI":"10.1093\/nar\/gkac963","volume":"51","author":"M Kanehisa","year":"2023","unstructured":"Kanehisa M, Furumichi M, Sato Y, Kawashima M, Ishiguro-Watanabe M. KEGG for taxonomy-based analysis of pathways and genomes. Nucleic Acids Res. 2023;51(D1):D587\u201392. https:\/\/doi.org\/10.1093\/nar\/gkac963.","journal-title":"Nucleic Acids Res."},{"issue":"9","key":"18556_CR27","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1038\/ng1861","volume":"38","author":"SL Carter","year":"2006","unstructured":"Carter SL, Eklund AC, Kohane IS, Harris LN, Szallasi Z. A signature of chromosomal instability inferred from gene expression profiles predicts clinical outcome in multiple human cancers. Nat Genet. 2006;38(9):1043\u20138. https:\/\/doi.org\/10.1038\/ng1861.","journal-title":"Nat Genet."},{"issue":"26","key":"18556_CR28","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.1016\/j.omtn.2021.10.014","volume":"20","author":"S Zhuang","year":"2021","unstructured":"Zhuang S, Chen T, Li Y, Wang Y, Ai L, Geng Y, Zou M, Liu K, Xu H, Wang L, Zhao Z, Chang Z, Gu Y. A transcriptional signature detects homologous recombination deficiency in pancreatic cancer at the individual level. Mol Ther Nucleic Acids. 2021;20(26):1014\u201326. https:\/\/doi.org\/10.1016\/j.omtn.2021.10.014.","journal-title":"Mol Ther Nucleic Acids."},{"issue":"1","key":"18556_CR29","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1007\/s00535-020-01730-7","volume":"56","author":"K Tezuka","year":"2021","unstructured":"Tezuka K, Okamura Y, Sugiura T, Ito T, Yamamoto Y, Ashida R, Ohgi K, Uesaka K. The influence of familial pancreatic cancer on postoperative outcome in pancreatic cancer: relevance to adjuvant chemotherapy. J Gastroenterol. 2021;56(1):101\u201313. https:\/\/doi.org\/10.1007\/s00535-020-01730-7.","journal-title":"J Gastroenterol."},{"issue":"10","key":"18556_CR30","doi-asserted-by":"publisher","first-page":"1784","DOI":"10.1007\/s10147-021-02015-6","volume":"26","author":"K Abe","year":"2021","unstructured":"Abe K, Kitago M, Kitagawa Y, Hirasawa A. Hereditary pancreatic cancer. Int J Clin Oncol. 2021;26(10):1784\u201392. https:\/\/doi.org\/10.1007\/s10147-021-02015-6.","journal-title":"Int J Clin Oncol."},{"issue":"17","key":"18556_CR31","doi-asserted-by":"publisher","first-page":"4244","DOI":"10.3390\/cancers15174244","volume":"15","author":"GF Parisi","year":"2023","unstructured":"Parisi GF, Papale M, Pecora G, Rotolo N, Manti S, Russo G, Leonardi S. Cystic fibrosis and cancer: unraveling the complex role of CFTR gene in cancer susceptibility. Cancers. 2023;15(17):4244. https:\/\/doi.org\/10.3390\/cancers15174244.","journal-title":"Cancers."},{"issue":"2","key":"18556_CR32","doi-asserted-by":"publisher","first-page":"167","DOI":"10.4161\/cbt.3.2.609","volume":"3","author":"CD Rogers","year":"2004","unstructured":"Rogers CD, van der Heijden MS, Brune K, Yeo CJ, Hruban RH, Kern SE, Goggins M. The genetics of FANCC and FANCG in familial pancreatic cancer. Cancer Biol Ther. 2004;3(2):167\u20139. https:\/\/doi.org\/10.4161\/cbt.3.2.609.","journal-title":"Cancer Biol Ther."},{"issue":"7","key":"18556_CR33","doi-asserted-by":"publisher","first-page":"e2170","DOI":"10.1002\/mgg3.2170","volume":"11","author":"H Jiang","year":"2023","unstructured":"Jiang H, Huang F, Chen X, Zhang L, Shen M, Pan B, Wang B, Guo W. Germline mutations in homologous recombination repair genes among Chinese pancreatic ductal adenocarcinoma patients detected using next-generation sequencing. Mol Genet Genomic Med. 2023;11(7):e2170. https:\/\/doi.org\/10.1002\/mgg3.2170.","journal-title":"Mol Genet Genomic Med."},{"issue":"2","key":"18556_CR34","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1111\/pin.12133","volume":"64","author":"T Nakaya","year":"2014","unstructured":"Nakaya T, Kurata A, Hashimoto H, Nishimata S, Kashiwagi Y, Fujita K, Kawashima H, Kuroda M. Young-age-onset pancreatoduodenal carcinoma in Shwachman-Diamond syndrome. Pathol Int. 2014;64(2):75\u201380. https:\/\/doi.org\/10.1111\/pin.12133.","journal-title":"Pathol Int."},{"issue":"10","key":"18556_CR35","doi-asserted-by":"publisher","first-page":"2594","DOI":"10.3324\/haematol.2023.282949","volume":"108","author":"N Kawashima","year":"2023","unstructured":"Kawashima N, Oyarbide U, Cipolli M, Bezzerri V, Corey SJ. Shwachman-Diamond syndromes: clinical, genetic, and biochemical insights from the rare variants. Haematologica. 2023;108(10):2594\u2013605. https:\/\/doi.org\/10.3324\/haematol.2023.282949.","journal-title":"Haematologica."},{"issue":"23","key":"18556_CR36","doi-asserted-by":"publisher","first-page":"2401","DOI":"10.1001\/jama.2018.6228","volume":"319","author":"C Hu","year":"2018","unstructured":"Hu C, Hart SN, Polley EC, Gnanaolivu R, Shimelis H, Lee KY, Lilyquist J, Na J, Moore R, Antwi SO, Bamlet WR, Chaffee KG, DiCarlo J, Wu Z, Samara R, Kasi PM, McWilliams RR, Petersen GM, Couch FJ. Association between inherited germline mutations in cancer predisposition genes and risk of pancreatic cancer. JAMA. 2018;319(23):2401\u20139. https:\/\/doi.org\/10.1001\/jama.2018.6228.","journal-title":"JAMA."},{"issue":"12","key":"18556_CR37","doi-asserted-by":"publisher","first-page":"2704","DOI":"10.1158\/1078-0432.CCR-21-3581","volume":"28","author":"PA Philip","year":"2022","unstructured":"Philip PA, Azar I, Xiu J, Hall MJ, Hendifar AE, Lou E, Hwang JJ, Gong J, Feldman R, Ellis M, Stafford P, Spetzler D, Khushman MM, Sohal D, Lockhart AC, Weinberg BA, El-Deiry WS, Marshall J, Shields AF, Korn WM. Molecular characterization of KRAS wild-type tumors in patients with pancreatic adenocarcinoma. Clin Cancer Res. 2022;28(12):2704\u201314. https:\/\/doi.org\/10.1158\/1078-0432.CCR-21-3581.","journal-title":"Clin Cancer Res."}],"container-title":["Annals of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-025-18556-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1245\/s10434-025-18556-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-025-18556-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,5]],"date-time":"2026-01-05T13:09:24Z","timestamp":1767618564000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1245\/s10434-025-18556-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,14]]},"references-count":37,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["18556"],"URL":"https:\/\/doi.org\/10.1245\/s10434-025-18556-3","relation":{},"ISSN":["1068-9265","1534-4681"],"issn-type":[{"type":"print","value":"1068-9265"},{"type":"electronic","value":"1534-4681"}],"subject":[],"published":{"date-parts":[[2025,10,14]]},"assertion":[{"value":"27 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no conflicts of interest in association with the present study.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosure"}},{"value":"The Shizuoka Cancer Center initiated Project HOPE (High-Tech Omics-Based Patient Evaluation) in 2014 to investigate the biological characteristics and pathogenesis of various cancers, following approval from the Institutional Review Board of Shizuoka Cancer Center (approval no. 25-33). Project HOPE was conducted at a single institution and was designed in accordance with the Ethical Guidelines for Human Genome and Genetic Analysis Research, as revised in 2013. Written informed consent was obtained from all patients participating in Project HOPE.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}